Capstone Investment Advisors
BBIO icon

Capstone Investment Advisors’s BridgeBio Pharma BBIO Stock Holding History

Capstone Investment Advisors’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-4,420
Closed -$230K – 1608
2025
Q3 		$230K Buy
+4,420
New +$216K ﹤0.01% 1764
2024
Q2 		– Sell
-83,540
Closed -$2.58M – 2085
2024
Q1 		$2.58M Buy
+83,540
New +$2.84M 0.01% 676
2023
Q4 		– Sell
-14,468
Closed -$382K – 2118
2023
Q3 		$382K Buy
+14,468
New +$411K ﹤0.01% 1464

Other funds holding BBIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capstone Investment Advisors's BBIO Position: Q4 2025 in Review

Capstone Investment Advisors sold out of BridgeBio Pharma (BBIO) in Q4 2025, closing a stake of 4,420 shares — an estimated $230K sold.

Capstone Investment Advisors first reported a position in BBIO in Q3 2023 and held it in 3 quarters. The position peaked at $2.58M in Q1 2024. 433 funds tracked by Wall St. Rank hold BBIO as of Q4 2025.

  • Capstone Investment Advisors reported no remaining BridgeBio Pharma position as of Q4 2025 after selling out during the quarter.
  • Capstone Investment Advisors sold 4,420 BridgeBio Pharma shares in Q4 2025, an estimated $230K.
  • Capstone Investment Advisors first reported a position in BridgeBio Pharma in Q3 2023 and held it in 3 quarters.
  • Capstone Investment Advisors's BridgeBio Pharma position peaked at $2.58M in Q1 2024.
  • 433 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q4 2025.

Based on Capstone Investment Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.